%20PNG.png)
The Multi-Omics Revolution in Clinical Trials
This research paper highlights the 2026 shift from simple genomics to "Dynamic Systems Engineering" in drug development.
Multi-Omics Integration: Leading clinical trials in 2026 now layer genomics (DNA) with proteomics (proteins), transcriptomics (RNA), and metabolomics (metabolites) to create a high-resolution map of a patient's molecular dysfunction.
Digital Twins: Pharmaceutical companies now use "digital twin" simulations to model how a drug will interact with specific patient subgroups before the first human dose.
Impact: This molecular "matching" has led to smaller, faster, and more successful trials. By 2026, it is projected that 75% of new drug discoveries involve some form of AI-powered predictive modeling in the R&D process.
4 Views